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Intensive Care UnitAbstract Purpose: Evaluate the potential Drug–Drug Interactions (pDDI) found in prescription
orders of adult Intensive Care Unit (ICU) of a Brazilian public health system hospital; quantify and
qualify the pDDI regarding their severity and risks to the critical patient, using the database from
Micromedex.
Methods: Prospective study (January–December of 2011) collecting and evaluating 369 prescrip-
tion orders (convenient sampling), one per patient.
Results: During the study 1844 pDDIs were identiﬁed and distributed in 405 pairs (medication
A · medication B combination). There was an average of 5.00 ± 5.06 pDDIs per prescription
order, the most prevalent being moderate and important interactions, present in 74% and 67%
of prescription orders, respectively. In total, there were 9 contraindicated, 129 important and 204
moderate pDDIs. Among them 52 had as management recommendation to ‘‘avoid concomitanthrome P
Granja),
Clinical relevancy and risks of potential drug–drug interactions 367use’’ or ‘‘suspension of medication’’, while 306 had as recommendation ‘‘continuous and adequate
monitoring’’.
Conclusion: The high number of pDDIs found in the study combined with the evaluation of the
clinical relevancy of the most frequent pDDIs in the ICU shows that moderate and important inter-
actions are highly incident. As the majority of them demand monitoring and adequate management,
being aware of these interactions is major information for the safe and individualized risk manage-
ment.
ª 2014 TheAuthors. Production and hosting by Elsevier B.V. on behalf of King SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Due to the highly complex environment of ICUs and for the
great number of medications that most critical patient need,
their prescription orders are more predisposed to have poten-
tial Drug–Drug Interactions (pDDIs) (Cullen et al., 1997;
Papadopoulos and Smithburger, 2010). The prevention of
adverse events caused by potential interactions and their man-
agement are activities of the most importance in the practice of
clinical pharmacy in Intensive Care Units, being seen as one of
the ﬁrst actions to be developed in the clinical pharmacy ser-
vices (Chisholm-Burns et al., 2010; Leape et al., 1999).
Drug–drug interaction is deﬁned as a pharmacological or
clinical response to the administration of two or more drugs
that is different from the response they initiate when individu-
ally administered (David and Tatro, 2012). The knowledge of
the pharmacological characteristics of the drug interactions
assists in their clinical management. The access to databases
with detailed information on the pDDIs involved risks, their
mechanism of action and management orientation largely col-
laborate with the prevention of adverse events (Blix et al.,
2008; Duan et al., 2011; Papadopoulos and Smithburger,
2010).
Currently there are many evidences about the existence of
an important relationship between the adverse events and the
presence of drug interactions. A study developed by Plaza
et al. (2010) in Chile pointed out in its results that 23% of clin-
ically signiﬁcant adverse events observed in the studied ICU
during the research were related to drug interactions.
It was also demonstrated the need for continuous education
actions linked to the presence of interactions and the use of
computerized systems for their detection, which can result in
satisfactory diminishing of prescription orders with potential
interactions (Paterno et al., 2009; Smithburger et al., 2011;
Wright et al., 2012).
Here is accentuated the necessary collaboration among the
interactions alert systems and their critical evaluation by the
intensivist team. The achievement of ideal results concerning
the prevention of interactions combines alert systems with
the pharmacist’s professional evaluation, avoiding the expo-
sure of the clinical team to the ‘‘alert fatigue’’, expression that
represents the great number of interactions signaled by the sys-
tems while not all being clinically relevant. Even though the
whole clinical decision is individualized and requires a judi-
cious evaluation on a case by case basis, it is evident the need
for the critical evaluation of the clinical relevancy of the preva-
lent pDDIs in ICU outlining their risk proﬁle and collecting
information about their management and frequency in ICU
prescription orders (Smithburger et al., 2010a,b, 2011, 2012).2. Materials and methods
This is an observational, transverse study with a prospective
data compilation (January–December of 2011). This research
was carried out in a general adult ICU, with 24 beds, of a ter-
tiary university hospital with a total of 403 beds. This is a ref-
erence hospital in the area and it belongs to the public health
system.
The study group is composed of patients admitted to the
studied ICU during the data collection period. This is a general
ICU, tending for potentially critical patients or patients with
an unbalance of one or more organic systems due to high-
complexity surgeries, grave infections and other clinical
situations that demand intensive life support. The inclusion
criteria were admission in ICU for more than 24 h, be 18 or
older and have valid prescription orders with 2 or more drugs.
Every included patient had only one prescription order ana-
lyzed, selected among the valid prescription orders on the day
of the data collection. The prescription orders were assembled
from the central dispensation pharmacy of the institution and
were not screened by admission date. The research´s database
included prescription orders of different stages of admission
in the ICU (day one of admission, day 15, day 45, etc.). The
compilation was always done in the mornings, once a week,
respecting the maximum limit of 10 prescription orders per
day, a number permitting a full analysis by just one profes-
sional. Prescription orders were collected only when the
researcher was present at the institution, characterizing a sam-
pling by convenience. For ethical and professional reasons,
there were made isolated interventions in a verbal form to
the medical team when clinically relevant pDDIs were identi-
ﬁed (moderate to contraindicated).
Quantiﬁcation and classiﬁcation of the pDDIs was done
using the database from Micromedex (Thomson Reuters
2011). The information used for the identiﬁcation and classiﬁ-
cation of the pDDIs in this study was those available at
Micromedex in 2011, when the data were analyzed. It is impor-
tant to accentuate that this database is daily updated, indicat-
ing that the information used in this study may not be the same
available by the current version from Truven 2014. The pDDIs
were classiﬁed according to the information contained in this
database, which regards the interactions whose drugs are con-
traindicated for concomitant use as ‘‘contraindicated’’, the
pDDIs that can represent life threat and/or require medical
intervention to diminish or avoid serious adverse effects as
‘‘important’’, those that can result in aggravation of the
patient´s health problem and/or require a treatment alteration
as ‘‘moderate’’ and those that could result in limited clinical
effects that include increase in frequency or severity of colat-
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alteration as ‘‘secondary’’.
In this study, only the interactions classiﬁed as moderate,
important or contraindicated in the clinical decision support
system Micromedex are considered clinically relevant.
Descriptive statistics was used to delineate the sampling
proﬁle. Statistical analysis was performed using the SAS Sys-
tem for Windows (Statistical Analysis System), version 9.2
SAS Institute Inc. 2002–2008, Cary, NC, USA. This project
fulﬁlled all the ethical requirements for research involving
human beings, having the approval of the Ethical Committee
in Research of the institution.
3. Results
From January to December of 2011 were analyzed prescrip-
tion orders of 369 patients (1 prescription per patient), mean
age of 57.03 ± 14.62, admitted for at least 24 h in the adult
Intensive Care Unit of HC – UNICAMP (average of hospital-
ization in adult ICU= 13.34 ± 16.49 days). The study group
(205 men and 164 women) represents approximately 37% of
the population admitted in the ICU during this period, which
has 24 beds and receives about a thousand patients per year. In
the assessed period 205 different types of drugs were pre-
scribed, (13.04 ± 4.26 per prescription order). Table 1 shows
the distribution of the drugs observed in this study according
to the Anatomical Therapeutic Chemical (ATC) Classiﬁcation.
During the study there were 1844 pDDIs identiﬁed, quanti-
ﬁed, classiﬁed and distributed in 405 combinations among theTable 1 Frequency of prescription per ATC Class.
ATC class
A – Alimentary tract and metabolism
B – Blood and blood forming organs
C – Cardiovascular system
D – Dermatologicals
G – Genitourinary system and sex hormones
H – Systemic hormonal prep, excluding sex hormones
J – General antiinfectives for systemic use
L – Antineoplastic and immunomodulating agents
M – Musculo-skeletal system
N – Nervous system
R – Respiratory system
S – Sensory organs
V – Various
Table 2 Frequency of total pDDIs and Clinically Relevant pDDIs
ATC Class pDDI types (n (
A – Alimentary tract and metabolism 73 (9.7)
B – Blood and blood forming organs 90 (11.9)
C – Cardiovascular system 185 (24.6)
D – Dermatologicals 6 (0.8)
H – Systemic hormonal prep, excluding sex hormones 25 (3.3)
J – General antiinfectives for systemic use 87 (11.6)
L – Antineoplastic and immunomodulating agents 27 (3.6)
M – Musculo-skeletal system 23 (3.0)
N – Nervous system 215 (28.6)
R – Respiratory system 20 (2.6)
S – Sensory organs 1 (0.1)prescribed drugs. In the analyzed prescription 89% presented
at least one pDDI, the emphasis being on the prevalence of
moderate and important interactions, present in 74% and
67% of prescription orders, respectively. Table 2 shows inter-
actions distribution by ATC classiﬁcation, their total fre-
quency in prescription orders and the frequency of the
considered clinically relevant interactions.
It was observed a number of potential interactions classiﬁed
as contraindicated representing 7% of pDDIs found in the
analyzed prescription orders. Metoclopramide is the drug most
involved in this severity class of pDDIs, being present in 6 out
of 12 listed types. By analyzing the risks associated with the
observed pDDIs it was possible to determine the frequency
for each physiological system, as presented by Table 3.
The pDDIs present in prescription orders analyzed in this
study that are considered clinically relevant have different
types of mechanism of action. The most prevalent are the ones
with additive pharmacological effects (n= 69) that potentially
lead to an exacerbation of the therapeutic function or of the
undesired adverse effects. The next most frequent are 68 inter-
actions caused by Cytochrome P450 (CYP450) induction or
inhibition, which alters the drug metabolism, then the ones
that lead to a possible therapeutic efﬁcacy loss or the release
of toxic metabolites that totalizes 65 interactions. Creatinine
clearance alteration mechanism accounts for 18 interactions,
and 17 point to a possible drug absorption reduction. Fifty
interactions still do not have their mechanisms enlighted.
Most observed pDDIs (316) have as management orienta-
tion the careful monitoring of the patients that need concom-Drugs types (n (%)) Prescription frequency (n (%))
30 (15.4) 1152 (24.8)
19 (9.4) 771 (16.6)
34 (16.9) 779 (16.7)
5 (2.5) 14 (0.3)
1 (0.5) 1 (0.0)
7 (3.4) 147 (3.2)
39 (19.4) 433 (9.3)
7 (3.4) 41 (0.9)
6 (2.9) 20 (0.4)
37 (18.4) 1007 (21.7)
11 (5.6) 275 (5.9)
1 (0.5) 3 (0.0)
1 (0.5) 3 (0.0)
per ATC Class.
%)) pDDIs frequency (n (%)) Clinically relevant pDDIs (n (%))
367 (10.4) 361 (10.21)
613 (17.3) 570 (16.1)
840 (23.8) 705 (19.9)
37 (1.0) 36 (10.0)
87 (2.5) 56 (1.6)
321 (9.1) 274 (7.7)
62 (1.7) 62 (1.7)
152 (4.3) 70 (2.0)
981 (27.8) 831 (23.5)
73 (2.1) 34 (0.9)
1 (0.0) 1 (0.0)
Table 3 Prevalent Risks among the found pDDIs.
Risks for each system associated to the pDDIs pDDI types (n (%)) pDDI frequency (n (%))
Respiratory (respiratory depression or bronchospasm) 17 (5.5) 83 (6.0)
Central nervous system alterations 62 (20.0) 284 (20.6)
Cardiovascular risk (alterations in QT, alterations in pressure control and other) 94 (30.3) 334 (24.3)
Hepatotoxicity 1 (0.3) 1 (0.07)
Renal (nephrototoxicity and/or ARI) 4 (1.3) 16 (1.2)
Coagulation alterations 50 (16.1) 313 (22.7)
Other 82 (26.5) 345 (25.1)
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monographies. In addition, possible dose adjustment need was
recommended for 31 pDDIs, while 52 had the instruction to
‘‘avoid concomitant use’’ or ‘‘suspend the use of one of the
two drugs involved’’.
4. Discussion
With 89.1% of the prescription orders presenting at least one
pDDI, it is evident the need for evaluation and accompani-
ment of the risks associated with drug therapy. It is important
to notice that this number includes all pDDI classes from the
contraindicated to the secondary (usually with no clinical rele-
vancy). All four classes are present in the studied pDDIs and
the most frequent interactions are those called ‘‘important’’.
The most recurrent ‘‘important’’ pDDI observed was the inter-
action between dipyrone and enoxaparin. Its clinical manage-
ment states the suspension of dipyrone or if maintained, that a
continuous monitoring of bleeding episodes is carried out
(Micromedex, 2011). Despite this instruction, little is known
about the real incidence of this interaction, being necessary the
judicious evaluation done in a case by case basis to establish
the risk beneﬁt relation between the suspension or mainte-
nance with continuous monitoring of this drug therapy. This
example is followed by most management orientations, that
always aim for the risk beneﬁt relation concerning the drug
therapy and the patient´s health.
One of the ﬁndings of this study was the observation of
contraindicated interactions, highlighting the presence of met-
oclopramide in most of them (79.4%). These interactions call
attention to the gravity of their possible consequences, such
as interactions between metoclopramide and neuroleptic
agents, when the risk of the rare syndrome known as Malig-
nant Neuroleptic Syndrome is enlarged. Considering this risk,
this class of interactions is to be avoided and symptoms mon-
itored and treatment protocol of possible adverse events if this
combination is inevitable must be known (Micromedex,
2011). These interactions represent an example of maximum
severity pDDI. When these are detected in ICU’s prescription
orders they must be cautiously analyzed to determine the risk
beneﬁt relation to the patient.
Even though a great number of drug interactions are clas-
siﬁed by the clinical decision support systems as important,
many of them do not present clinical relevancy in a closely
monitored environment such as an Intensive Care Unit. For
instance, this study presented many pDDIs found in prescrip-
tion orders that have clinical relevancy in the theoretical anal-
ysis being classiﬁed as Important or Moderate, yet in practice
do not offer signiﬁcant risks to the patients. Among the
involved risks of these interactions the adverse events relatedto respiratory depression are highlighted (23.5%), a kind of
risk that has a different approach in intensive therapy, since
a great amount of the patients could be under mechanic venti-
lation and all patients have close cardio and respiratory mon-
itoring. This type of analysis shows that these interactions
when looked under a broader perspective represent a smaller
risk and clinical relevancy in an ICU than in other wards of
the hospital. It is important to remember that other interac-
tions, involving the same drugs requires a more detailed
analysis on dose adjustment or pharmacotherapy alteration,
such as Fentanyl that is dealkylated by CYP3A4 with high-
hepatic-extraction ratios. The pharmacokinetics does not
change when administered with inhibitors, but requires a
greater dose when patients are in a long-term treatment with
inducers (carbamazepine, phenytoin), being clinically relevant
(Spriet et al., 2009).
Askari et al. (2013) study, conducted from 2002 to 2009 fol-
lowed 9644 admissions in a 30-bed ICU and 3892 (11.2%) of
these presented pDDIs. When the intensive therapy team ana-
lyzed the interactions, only 36 unique pairs of pDDIs were
considered relevant out of a total of 85. The difference between
the clinical relevancy classiﬁcations of the clinical decision sup-
port systems and the ones attributed by the ICU multidisci-
plinary team is demonstrated by the difference in the
averages of pDDIs found: our study had an average of
(5.0%) pDDIs per prescription order and the previously men-
tioned study had an average of 1.67 pDDIs per admission
(Askari et al., 2013).
In the same manner as our study, Uijtendaal et al., 2014 ret-
rospective study in a 32-bed ICU with 1659 patients and
35,784 prescription orders, indicated a high number of pDDIs
that require only continuous monitoring as clinical manage-
ment action (81%). The prospective study of Hasan et al.
(2012), that assessed pDDIs incidence in a 13-bed ICU in
Malaysia, evaluated the adverse events together with monitor-
ing of laboratory test, physical and mental examinations of the
patients with DDIs. It was also equally pointed out a great
number of pDDIs (402, average of 6.5 per patient) however;
few of them were clinically relevant (64, 15.9%). In this study
the prevalence of moderate DDIs (68.9%) corresponds with
the number found in our study (74.0%) (Hasan et al., 2012).
In the 2010 and 2012 studies completed by Smithburger
et al. it is possible to observe the difference between the clinical
relevancy pDDIs classiﬁcation attributed by intensivist doctors
and pharmacists and the severity classiﬁcation applied by the
databases. It is evident in the literature as well as in this
research that the high number of moderate, important and
contraindicated pDDIs found in prescription orders does not
necessarily correspond to the clinical relevancy of these inter-
actions in intensive therapy (Smithburger et al., 2010a,b,
370 A.T. Rodrigues et al.2012). Studies like these testify to the need of correlation of the
interactions present in the prescription orders, the laboratory
tests and the patient’s clinical parameters.
The information about the pDDIs helps in their critical
analysis avoiding that an excess of non-relevant alerts reach
the multidisciplinary team. The analysis and screening of these
pDDIs by the intensivist pharmacists make their discussion
with the prescribers more objective and effective, what pre-
vents the alert fatigue of the team.
5. Conclusions
Therefore it is possible to conclude that it is extremely impor-
tant to analyze the more frequent pDDIs in ICU, expanding
the information about them which contributes to the appropri-
ate management of the pharmacotherapy used in intensive
therapy. Acknowledging that the elevated number of pDDIs
would probably be signiﬁcantly reduced when clinically ana-
lyzing them in an intensive environment evidences the need
to confront the theoretical information from databases and
the literature to the knowledge of the multidisciplinary team
and the patient’s parameters. The ultimate goal of gathering
more information about the incidence of adverse events caused
by DDIs and the judicious analysis of these interactions when
present in ICU prescription orders, is the safety of the patient
and the optimization of their pharmacotherapy.
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